Ketamine Clinic Safety Standards: What Patients Should Expect

The Need for Standards

The rapid growth of ketamine therapy for depression has outpaced the development of formal, universally adopted safety standards. Unlike FDA-approved drug therapies that come with standardized prescribing information and Risk Evaluation and Mitigation Strategies (REMS), off-label IV ketamine treatment operates without a centralized regulatory framework dictating how clinics should be set up, staffed, or operated. This has led to significant variability in clinical practice — from academic medical centers with rigorous protocols to standalone clinics with less standardized approaches.

Several professional organizations, including the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) and the American Psychiatric Association (APA), have published guidance documents and consensus statements aimed at establishing baseline safety expectations. While these are not legally binding regulations, they represent the field's current best practices and provide a framework that patients can use to evaluate potential providers.

Pre-Treatment Evaluation

A thorough pre-treatment evaluation is the foundation of safe ketamine therapy. Emerging standards consistently emphasize the following components:

Comprehensive psychiatric assessment: Before initiating ketamine, patients should undergo a detailed evaluation of their psychiatric history, including current diagnoses, previous treatments and their outcomes, substance use history, and family psychiatric history. This assessment should confirm that the patient meets criteria for a condition for which ketamine has demonstrated benefit — most commonly treatment-resistant depression (TRD).

Medical history and physical examination: Because ketamine can affect cardiovascular function (transient increases in blood pressure and heart rate), a medical history focused on cardiovascular risk factors is essential. Uncontrolled hypertension, recent myocardial infarction, unstable angina, and intracranial pathology associated with elevated intracranial pressure are commonly cited contraindications. A baseline assessment of blood pressure and heart rate should be documented.

Medication review: A complete medication list should be reviewed for potential interactions, with particular attention to serotonergic medications (SSRIs, SNRIs, MAOIs), benzodiazepines (which may attenuate ketamine's effects), and other psychoactive substances. Patients should be screened for active substance use disorders, particularly involving ketamine or other dissociative drugs.

Informed consent: Patients should receive clear, written information about the off-label nature of ketamine therapy (for non-esketamine formulations), expected effects and side effects, the treatment protocol, risks including dissociation and misuse potential, alternative treatment options, and costs. Informed consent should be documented in the medical record.

During Treatment: Monitoring Standards

Clinical monitoring during ketamine administration represents one of the most important safety considerations. Consensus guidelines generally recommend:

Vital sign monitoring: Blood pressure, heart rate, and oxygen saturation should be measured at baseline, at regular intervals during treatment (typically every 15 to 30 minutes for IV infusions), and post-treatment before discharge. Pulse oximetry provides continuous monitoring of respiratory status.

Clinical observation: A qualified healthcare professional should be present and observing the patient throughout the treatment session. The level of monitoring should be proportionate to the route of administration — IV infusions typically warrant closer monitoring than oral or sublingual formulations taken in a clinical setting. Staff should be trained to recognize and respond to adverse events including hypertensive urgency, respiratory depression, severe nausea, and paradoxical agitation.

Emergency preparedness: Clinics should have emergency equipment readily available, including supplemental oxygen, suction, bag-valve mask, automated external defibrillator (AED), and emergency medications. Staff should be trained in Basic Life Support (BLS) at minimum, with Advanced Cardiac Life Support (ACLS) capability preferred for clinics performing IV infusions.

Dissociation assessment: Clinicians should assess the degree of dissociation during treatment, as this subjective experience varies considerably between patients and sessions. While some degree of dissociation is expected and may correlate with therapeutic benefit, severe or distressing dissociative reactions should be managed with reassurance, environmental modification (reducing stimulation), and if necessary, dose adjustment.

Post-Treatment Protocols

Safe discharge from a ketamine treatment session requires several standard practices:

Recovery observation: Patients should be observed for a minimum of one to two hours after IV infusion (or an appropriate period after other routes) until acute effects have resolved. Discharge criteria should include stable vital signs, resolution of significant dissociation, ability to ambulate safely, and absence of ongoing nausea or vomiting.

Transportation requirements: Patients should not drive or operate heavy machinery for the remainder of the day following ketamine treatment. Clinics should verify that the patient has arranged safe transportation before beginning the session.

Follow-up communication: Patients should receive clear instructions about what to expect in the hours following treatment, warning signs that should prompt them to seek medical attention, and how to reach the treatment team with questions or concerns.

Provider Qualifications

There is no single credential required to administer ketamine for depression, and qualifications vary by state. However, safety-focused standards emphasize:

Medical oversight: Treatment should be supervised by a physician (MD or DO) or, where state law permits, an advanced practice provider with appropriate training and experience. The supervising clinician should have expertise in psychiatric diagnosis and treatment, as well as familiarity with ketamine's pharmacology and adverse effect management.

Staff training: All clinical staff involved in ketamine administration should receive specific training in ketamine pharmacology, monitoring protocols, adverse event recognition and management, and emergency response procedures.

Ongoing education: Given the rapidly evolving evidence base for ketamine therapy, providers should engage in continuing education specific to ketamine treatment and stay current with published guidelines and research.

At-Home Treatment Considerations

The growth of at-home ketamine programs — where patients receive sublingual or oral formulations prescribed via telehealth and shipped from compounding pharmacies — raises distinct safety considerations. Best practices for at-home protocols include:

• Requiring a designated treatment monitor (a sober adult) to be physically present during each session
• Providing detailed written and video instructions for safe administration
• Conducting regular follow-up assessments (via telehealth or in person) to monitor treatment response, side effects, and medication adherence
• Implementing systems to track medication dispensing and detect potential misuse
• Clear protocols for medication storage and disposal

Red Flags for Patients

When evaluating potential ketamine providers, patients should be cautious of practices that:

• Do not conduct a thorough psychiatric and medical evaluation before treatment
• Guarantee specific outcomes or cure rates
• Do not monitor vital signs during treatment
• Lack emergency equipment or trained medical staff
• Do not provide clear informed consent documentation
• Prescribe ketamine without establishing a treatment plan or follow-up schedule
• Are unwilling to communicate with the patient's existing mental health providers — for more guidance, see how to find a qualified ketamine provider

The Path Forward

The ketamine therapy field is gradually moving toward more standardized and evidence-based safety practices. The APA's 2017 consensus statement, subsequent ASKP3 guidelines, and ongoing professional education initiatives are all contributing to the development of a more uniform standard of care. As regulatory bodies, professional organizations, and accreditation programs continue to refine these standards, patients can expect increasing consistency and accountability across the treatment landscape.

References

• APA Consensus Statement on Ketamine for Depression — American Psychiatric Association (2017). Foundational guidance on clinical ketamine use.
• ASKP3 Clinical Guidelines — American Society of Ketamine Physicians, Psychotherapists and Practitioners consensus guidelines.
• Safety Considerations for Ketamine Use in Depression — Sanacora et al., American Journal of Psychiatry. Review of safety concerns and monitoring recommendations.
• FDA REMS for Esketamine (Spravato) — FDA-mandated safety program as a reference framework.
• WHO Essential Medicines Safety Monitoring — World Health Organization pharmacovigilance standards.